Cargando…

Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects

BACKGROUND: Bromocriptine-QR (a quick-release formulation of bromocriptine mesylate), a dopamine D2 receptor agonist, is a US Food and Drug Administrration–approved treatment for type 2 diabetes mellitus (T2DM). A 3070-subject randomized trial demonstrated a significant, 40% reduction in relative ri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gaziano, J. Michael, Cincotta, Anthony H., Vinik, Aaron, Blonde, Lawrence, Bohannon, Nancy, Scranton, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541616/ https://www.ncbi.nlm.nih.gov/pubmed/23316290 http://dx.doi.org/10.1161/JAHA.112.002279

Ejemplares similares

Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
Publicado: (2015)

Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus
por: Chamarthi, Bindu, et al.
Publicado: (2015)

Circadian‐timed quick‐release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus
por: Chamarthi, Bindu, et al.
Publicado: (2019)

Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes
por: Gaziano, J. Michael, et al.
Publicado: (2010)

Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes
por: Ramteke, Karuna Balwant, et al.
Publicado: (2011)

Brain Dopamine–Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects
por: Cincotta, Anthony H.
Publicado: (2023)

Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes
por: Mahajan, Rajiv
Publicado: (2009)

Bromocriptine and insulin sensitivity in lean and obese subjects
por: Bahler, L, et al.
Publicado: (2016)

The therapeutic effect of bromocriptine as mesylate and estradiol valerate on serum and blood biochemistry of common quails
por: ul- Abideen, Zain, et al.
Publicado: (2021)

Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
por: Missale, C., et al.
Publicado: (1995)

Prediction of response to bromocriptine in acromegaly.
por: Atkinson, A. B., et al.
Publicado: (1978)

Repurposing of Bromocriptine for Cancer Therapy
por: Seo, Ean-Jeong, et al.
Publicado: (2018)

Central Hyperthermia Treated with Bromocriptine
por: Natteru, P., et al.
Publicado: (2017)

Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects
por: Cincotta, Anthony H., et al.
Publicado: (2022)

Bromocriptine, a clinical and pharmacological review /
por: Thorner, Michael O.
Publicado: (1980)

Bromocriptine in type 2 diabetes mellitus
por: Shivaprasad, C., et al.
Publicado: (2011)

Optimization of Bromocriptine-Mesylate-Loaded Polycaprolactone Nanoparticles Coated with Chitosan for Nose-to-Brain Delivery: In Vitro and In Vivo Studies
por: Badran, Mohamed M., et al.
Publicado: (2023)

Management of pituitary tumour apoplexy with bromocriptine in pregnancy
por: Janssen, Nina M, et al.
Publicado: (2012)

Bromocriptine Does Not Alter Speed–Accuracy Tradeoff
por: Winkel, Jasper, et al.
Publicado: (2012)

Repositioning of bromocriptine for treatment of acute myeloid leukemia
por: Lara-Castillo, María Carmen, et al.
Publicado: (2016)

Effects of tolcapone and bromocriptine on cognitive stability and flexibility
por: Cameron, Ian G. M., et al.
Publicado: (2018)

Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases
por: Simon, Rebecca, et al.
Publicado: (2018)

Effects of bromocriptine mesylate on homocysteine and high-sensitivity C-reactive protein levels in patients with type-2 diabetes mellitus
por: Niafar, Mitra, et al.
Publicado: (2016)

Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy
por: Chopra, Sandeep, et al.
Publicado: (2012)

Dopaminergic Challenge With Bromocriptine in Patients With Severe Brain Injury
por: Celik, JB, et al.
Publicado: (2015)

Efficacy of bromocriptine on glycemic and metabolic control of prediabetic patients
por: Khalilzade, Saied Hossein, et al.
Publicado: (2015)

Bromocriptine inhibits proliferation in the endometrium from women with adenomyosis
por: Tang, Yiqun, et al.
Publicado: (2023)

Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control
por: Keche, Yogendra
Publicado: (2010)

Bromocriptine Therapy for the Treatment of Invasive Prolactinoma: The Single Institute Experience
por: Cho, Kyung Rae, et al.
Publicado: (2013)

AB086. The effect of Xuanju compound capsule combined with bromocriptine
por: Bian, Jun, et al.
Publicado: (2016)

Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study
por: Hilfiker-Kleiner, Denise, et al.
Publicado: (2017)

Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction
por: Haghikia, Arash, et al.
Publicado: (2018)

Role of bromocriptine in multi-spectral manifestations of traumatic brain injury
por: Munakomi, Sunil, et al.
Publicado: (2017)

A Systematic Review of the Utility of Bromocriptine in Acute Peripartum Cardiomyopathy
por: Badianyama, Marheb, et al.
Publicado: (2021)

Comparison of bromocriptine and hydroxyethyl starch in the prevention of ovarian hyperstimulation syndrome
por: Zhang, Qiaoli, et al.
Publicado: (2022)

Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models
por: Bai, Lijuan, et al.
Publicado: (2023)

Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet
por: Ezrokhi, Michael, et al.
Publicado: (2021)

Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients
por: Nagata, Eiichiro, et al.
Publicado: (2016)

Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study
por: Roe, Erin D., et al.
Publicado: (2015)

Correction: Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients
por: Nagata, Eiichiro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_soa80h7e1h7t7pqs639nvi99ra